Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update


Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA

Go here to read the rest:
Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Related Posts